ArticleDermatology and therapy2026
Dupilumab Reduces Pruritus in Clinically Distinct Dermatologic Diseases: Data from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 4 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Master Protocol of Three Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naïve to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab
A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable
A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAtopic dermatitis (AD), prurigo nodularis (PN), and chronic spontaneous urticaria (CSU) are chronic inflammatory skin diseases varying in clinical presentation but sharing the common and burdensome symptom of itch. Here, we investigate the efficacy of dupilumab in reducing pruritus in individuals with AD, PN, and CSU.
methodsLIBERTY-AD CHRONOS, LIBERTY-PN PRIME/PRIME2, and LIBERTY-CSU CUPID Study A were randomized, double-blind, placebo-controlled, phase III trials of dupilumab for AD, PN, and CSU, respectively. The itch-related study endpoints included the weekly average of daily Peak Pruritus Numeric Rating Scale (PP-NRS) for AD, weekly average of Worst Itch Numeric Rating Scale (WI-NRS) for PN, and total Itch Severity Score over 7 days (ISS7) for CSU. The efficacy endpoints included the proportion of patients who achieved a clinically meaningful improvement in PP-NRS (≥ 4-points), WI-NRS (≥ 4-points), or ISS7 (≥ 5-points); the percentage change in PP-NRS, WI-NRS, or ISS7; and the proportion of patients who achieved ≥ 50% reduction in PP-NRS, WI-NRS, or ISS7. Safety endpoints included treatment-emergent adverse events and severe adverse events.
resultsIn each trial, patients in both treatment groups demonstrated a severe pruritus burden at baseline on the respective itch scales (dupilumab versus placebo [Q1-Q3]; PP-NRS: 7.7 [6.6-8.5] versus 7.6 [6.3-8.6]; WI-NRS: 8.7 [7.9-9.3] versus 8.4 [7.9-9.1]; ISS7: 16.0 [14.0-20.0] versus 15.5 [13.0-20.0]). Dupilumab recipients were significantly more likely to achieve clinically meaningful improvements in PP-NRS (P < 0.0001), WI-NRS (P < 0.0001), and ISS7 (P = 0.0014) than placebo recipients. The percentage change from baseline was also significantly greater in dupilumab-treated patients than placebo recipients in all three trials (PP-NRS: P < 0.0001; WI-NRS: P < 0.0001; ISS7: P = 0.0009). Similarly, significantly more dupilumab versus placebo recipients achieved ≥ 50% reduction in relevant itch outcome scales in AD (70% versus 38.8%; P < 0.0001), PN (60.1% versus 20.9%; P < 0.0001), and CSU (68.6% versus 42.7%; P = 0.0213). Overall, safety was generally consistent with the known dupilumab safety profile.
conclusionsBaseline median pruritus in AD, PN, or CSU reached the upper third of the respective itch scales, demonstrating severe pruritus burden. In all three disease states, dupilumab treatment resulted in clinically meaningful improvement in itch.
trial registrationClinicalTrials.gov: NCT02260986, NCT04183335/NCT04202679, NCT04180488.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.